EGFR and glioblastoma: The results demonstrated that that EGFR.Sig exhibited superior predictive performance compared to other published gene signatures in the Zhao 2019 GBM cohort, while maintaining consistently robust predictive power relative to existing signatures across multiple independent validation cohorts (Figure 5C, Supplementary Table S2).